dr. wakelee on unmet needs for immunotherapy in nsclc
Published 5 years ago • 158 plays • Length 1:35Download video MP4
Download video MP3
Similar videos
-
2:21
dr. wakelee on the rationale for immunotherapy in nsclc
-
1:46
dr. wakelee on single-agent immunotherapy in nsclc
-
3:49
unmet needs: sequencing after immunotherapy in nsclc
-
1:32
dr. wakelee on immunotherapy versus targeted agents in nsclc
-
1:54
dr. wakelee on fda approval of frontline pembrolizumab in nsclc
-
2:18
dr. wakelee on first trial to combine antiangiogenesis agents with immunotherapy in nsclc
-
1:35
dr. wakelee discusses maintenance therapy for patients with lung cancer
-
1:49
immunotherapy and beyond for lung cancer prevention
-
2:15
dr. wakelee on birch trial for atezolizumab in patients with nsclc
-
1:19
dr. wakelee on combining targeted agents for the treatment of lung cancer
-
1:29
dr. wakelee on available treatments following tumor progression in lung cancer
-
1:55
dr. heather wakelee discusses nintedanib plus chemotherapy in nsclc
-
1:23
dr. wakelee discusses current state of treatment in nsclc
-
1:31
more is needed for immunotherapy in lung cancer
-
1:16
dr. wakelee on first-line therapy for egfr-mutant lung cancer
-
2:26
dr. fred r. hirsch on unmet needs in lung cancer
-
1:29
dr. camidge on the unmet needs for lung cancer
-
1:57
dr. wakelee on benefits of osimertinib in egfr-mutant nsclc treatment
-
1:23
dr. wakelee on veristrat testing in non-small cell lung cancer